IssuerAnnouncementDetailsV2Portlet
Actions
Middle East Pharmaceutical Industries Company “Avalon Pharma” announces the approval of the Saudi Food and Drug Authority (SFDA) to register new production lines at the company's Factory No. 2 in Riyadh
| Element List | Explanation |
|---|---|
| Announcement Detail | Middle East Pharmaceutical Industries Company "Avalon Pharma" is pleased to announce the approval of the Saudi Food and Drug Authority (SFDA) for the registration of new production lines at the company's Plant No. (2) in Riyadh city. The newly approved production lines include lines for capsules and tablets, as well as semi-solids, including creams, ointments, and gels. When fully operational, the newly registered lines will have a production capacity of 270 million tablets and capsules per year, while semi-solids will have a production capacity of 22 million units per year. Commercial production will commence on the new production lines upon obtaining the necessary approvals from the Saudi Food and Drug Authority (SFDA) relevant to the targeted products. For more information, please contact the company's Investor Relations Department at investors.relations@avalon.com.sa |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.
Share
Company Performance
Key Parameters
Last Price 141.0
Net Change -2.2 (-1.54%)
Value Traded (Sar) 12,825,377.8
Volume Traded 90,673
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions